What do systematic reviews say?

Summary of findings: pioglitazone monotherapy vs another pharmacological glucose‐lowering monotherapy

The review found no eligible studies for this question.

• Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Metformin vs insulin

The review found no eligible studies for this question.

• Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Metformin vs thiazolidinediones

It is very uncertain whether summary of findings of metformin monotherapy for adults with type 2… changes all‐cause mortality compared with thiazolidinediones (very low certainty).

• Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
  RR 0.88 [0.55, 1.39]
  5 studies · 4402 participants
  Very low

Metformin vs dipeptidyl‐peptidase 4 inhibitors

• Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 1977 participants
  Very low

Metformin vs glucagon like peptide‐1 analogues

• Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 807 participants
  Very low

Metformin vs meglitinides

The review found no eligible studies for this question.

• Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Metformin vs sulphonylureas

• Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 3129 participants
  Very low

Metformin‐sulphonylurea (second‐ or third‐generation) combination therapy vs metformin plus another antidiabetic drug

The review found no eligible studies for this question.

• Metformin and second‐ or third‐generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: pioglitazone monotherapy vs intensive behaviour‐changing intervention

The review found no eligible studies for this question.

• Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: pioglitazone monotherapy vs placebo

• Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk… 2020 · Cochrane Headline outcomes only
  2.38 [0.54, 10.5]
  4 studies · 1156 participants
  Very low

Summary of findings: pioglitazone monotherapy vs no intervention

It is very uncertain whether summary of findings: pioglitazone monotherapy changes all‐cause mortality (N) compared with no intervention (very low certainty).

• Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk… 2020 · Cochrane Headline outcomes only
  RR 0.85 [0.38, 1.91]
  3 studies · 866 participants
  Very low

Surgery vs preoperative pharmacological therapy and surgery

The review found no eligible studies for this question.

• Surgical and non‐surgical interventions for primary and salvage treatment of growth hormone‐secreting pituitary… 2024 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Surgery vs Pharmacological therapy

The review found no eligible studies for this question.

• Surgical and non‐surgical interventions for primary and salvage treatment of growth hormone‐secreting pituitary… 2024 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The review found no eligible studies for this question.

• Insulin monotherapy compared with the addition of oral glucose‐lowering agents to insulin for people with type 2… 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The review found no eligible studies for this question.

• Insulin monotherapy compared with the addition of oral glucose‐lowering agents to insulin for people with type 2… 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The review found no eligible studies for this question.

• Insulin monotherapy compared with the addition of oral glucose‐lowering agents to insulin for people with type 2… 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The review found no eligible studies for this question.

• Insulin monotherapy compared with the addition of oral glucose‐lowering agents to insulin for people with type 2… 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The review found no eligible studies for this question.

• Insulin monotherapy compared with the addition of oral glucose‐lowering agents to insulin for people with type 2… 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

• Radioiodine therapy versus antithyroid medications for Graves' disease 2016 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 425 participants
  GRADE not reported

Intervention not reported

The review found no eligible studies for this question.

• Sulphonylurea monotherapy for patients with type 2 diabetes mellitus 2013 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found